- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02112240
Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients
Novel Sentinel Lymph Node Mapping Technique in Early Stage Rectal Cancer
The purpose of this study is to see if investigators can develop a technique to identify sentinel lymph nodes in the rectum for rectal cancer patients with the use of a radiotracer (Tc-sulfur colloid), a dye (Spot), and imaging, both pre- and intraoperatively. Eligible patients are those with stage I-III rectal cancer undergoing standard low anterior resection or abdominoperineal resection.
Investigators hypothesize that use of a unique intraoperative lymphatic mapping technique using a mobile gamma camera will identify the sentinel lymph node in patients with rectal cancer with greater than 80% sensitivity.
Subjects will receive injections of the tracer and dye prior to surgery, have preoperative SPECT/CT imaging to be used as a guide to the rectal lymphatic system and then proceed to their scheduled surgery. During surgery, images of the rectum will be taken with a unique mobile gamma camera prior to removal and upon resection.
If surgeons are able to identify the sentinel lymph nodes surrounding the rectal tumor, the hope is to combine this technique with a less invasive surgery called transanal endoscopic microsurgery (TEM) for early stage rectal cancer patients.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- University of Virginia
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adult patients with stage I,II, or III rectal cancer undergoing standard trans- abdominal low anterior resection or abdominoperineal resection surgery at the University of Virginia
- Willing and able to give written informed consent
Exclusion Criteria:
- Patients less than 18 years of age
- Women who are pregnant and/or breastfeeding
- Prisoners
- Unable to give written informed consent
- Participants with medical contradictions or have potential problems complying with the requirements of the protocol, in the opinion of the investigator
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Surgery with pre- and intra-op imaging
Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot.
A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum.
Subjects will proceed to their standard surgery.
Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.
|
Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
Andre navne:
Dye injection for tattooing rectal tumor prior to surgical resection.
Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
Preoperative imaging to identify lymph nodes in rectum.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.
Tidsramme: At the time of surgery and the time of pathological review, an expected average of 7 days.
|
The primary endpoint is the sensitivity of sentinel lymph node (SLN) detection by the technique which will be estimated by the number of SLNs detected by the technique divided by the number noted at surgery or on final pathology review.
90% confidences interval around the estimate will help guide interpretation of the results.
|
At the time of surgery and the time of pathological review, an expected average of 7 days.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Feasibility
Tidsramme: From the time of tracer and dye injections to 30 day postoperative visit
|
Descriptive summaries will be used to list any complications that may have occurred pre-, intra- or post-operatively.
Frequency and location of the sentinel lymph node (SLN) with respect to the tumor prior to surgery will be noted.
In addition the location of the SLN in relation to the tumor will be documented during pathologic examination with the pathologist and surgeon to assess the feasibility of excision with transanal endoscopic microsurgery.
|
From the time of tracer and dye injections to 30 day postoperative visit
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Traci L Hedrick, MD, University of Virginia
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 16746
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Endetarmskræft
-
Chinese PLA General HospitalIkke rekrutterer endnu
-
Gruppo Oncologico Italiano di Ricerca ClinicaGlaxoSmithKlineIkke rekrutterer endnu
-
National Cancer Institute, NaplesRekrutteringLocally Advanced Rectal Cancer (LARC)Italien
-
Cai ZerongAfsluttet
-
Beijing Friendship HospitalRekrutteringLocally Advanced Rectal Cancer (LARC)Kina
-
First Affiliated Hospital of Wenzhou Medical UniversityRekrutteringLocally Advanced Rectal Cancer (LARC)Kina
-
Peking Union Medical College HospitalRekrutteringLocally Advanced Rectal Cancer (LARC)Kina
-
Guangdong Provincial People's HospitalAktiv, ikke rekrutterendeLocally Advanced Rectal Cancer (LARC)Kina
-
Xinhua Hospital, Shanghai Jiao Tong University...Aktiv, ikke rekrutterende
-
First Affiliated Hospital of Zhejiang UniversityNingbo Medical Center Lihuili Hospital; Second Affiliated Hospital of Wenzhou... og andre samarbejdspartnereRekrutteringLocally Advanced Rectal Cancer (LARC)Kina
Kliniske forsøg med Intraoperative Mobile Gamma Camera imaging
-
College of Medical Sciences Teaching Hospital....UkendtZygomatisk buebrud
-
Columbia UniversityActinium PharmaceuticalsRekrutteringSeglsygdom på grund af hæmoglobin SForenede Stater
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI)AfsluttetPædiatrisk hjertetransplantation | Pædiatriske hjertetransplantationsmodtagereForenede Stater, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringAkut myeloid leukæmi | Myelodysplastisk syndrom | Pode versus værtssygdomForenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeGliom | Hæmatopoietisk og lymfoid celle-neoplasma | Melanom | Lymfom | Myelomatose | Tilbagevendende ovariekarcinom | Brystkarcinom | Tilbagevendende hoved- og halskarcinom | Tilbagevendende lungekarcinom | Tilbagevendende hudkarcinom | Gastrisk karcinom | Avanceret lymfom | Avanceret malignt fast neoplasma | Refraktær... og andre forholdForenede Stater, Puerto Rico, Guam
-
National Cancer Institute (NCI)RekrutteringNeuroblastom | Ganglioneuroblastoma, nodulærForenede Stater, Canada, Puerto Rico, Australien, New Zealand